000 02981nam  2200361za 4500
0019.855992
003CaOODSP
00520200618101622
007cr |||||||||||
008180430s2018    onc     ob   f000 0 eng d
020 |a9780660264387
040 |aCaOODSP|beng
043 |an-cn---
0861 |aHP40-213/2018E-PDF
24500|aNACI literature review on the comparative effectiveness and immunogenicity of subunit and split virus inactivated influenza vaccines in adults 65 years of age and older |h[electronic resource].
2461 |iAt head of title: |aAdvisory committee review, National Advisory Committee on Immunization (NACI)
260 |a[Ottawa] : |bPublic Health Agency of Canada, |c2018.
300 |a29 p.
500 |aIssued also in French under title: Revue de la littérature du CCNI sur l’efficacité comparative et l’immunogénicité du vaccin antigrippal inactivé sous unitaire et du vaccin antigrippal inactivé à virion fragmenté chez les adultes âgés de 65 ans et plus.
500 |aCover title.
500 |a"Publication date: May 2018."
500 |aPrepared by: K. Young ... [et al.]. Cf. Acknowledgements.
504 |aIncludes bibliographical references (p. 13-14).
516 |aElectronic monograph in PDF format.
520 |a"Subunit and split virus inactivated influenza vaccines are two commonly used types of seasonal influenza vaccines, and continue to dominate the market in Canada. Although these two formulations of influenza vaccine have been available for many decades, NACI has not previously conducted a literature review to investigate the comparative vaccine effectiveness of these different formulations. A difference in vaccine effectiveness between these formulations would be especially important for older adults (65 years of age or older), since there is evidence that older adults experience more severe illness due to influenza and have reduced vaccine effectiveness compared to younger adults. To address this gap, NACI conducted a literature review to examine the vaccine effectiveness and immunogenicity of unadjuvanted, standard dose subunit inactivated influenza vaccines compared to unadjuvanted, standard dose split virus inactivated influenza vaccines in adults 65 years of age and older"--Executive summary, p. 3.
69207|2gccst|aSeniors
69207|2gccst|aImmunization
69207|2gccst|aInfluenza
7101 |aCanada. |bNational Advisory Committee on Immunization.
7102 |aPublic Health Agency of Canada.
77508|tRevue de la littérature du CCNI sur l’efficacité comparative et l’immunogénicité du vaccin antigrippal inactivé sous unitaire et du vaccin antigrippal inactivé à virion fragmenté chez les adultes âgés de 65 ans et plus |w(CaOODSP)9.855993
85640|qPDF|s1.25 MB|uhttp://publications.gc.ca/collections/collection_2018/aspc-phac/HP40-213-2018-eng.pdf